Carcinoma, Non-Small Cell Lung Clinical Trials in Budapest

7 recruitingBudapest, Hungary

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC1,065 enrolled47 locationsNCT04165798
Recruiting
Phase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC680 enrolled225 locationsNCT06623422
Recruiting
Phase 3

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled353 locationsNCT06890598
Recruiting
Phase 2

THIO Sequenced With Cemiplimab in Advanced NSCLC

Carcinoma, Non-Small Cell Lung
Maia Biotechnology227 enrolled33 locationsNCT05208944